Stocklytics Platform
Asset logo for symbol TRDA
Entrada Therapeutics
TRDA63
$16.98arrow_drop_up0.59%$0.10
Asset logo for symbol TRDA
TRDA63

$16.98

arrow_drop_up0.59%

Income Statement (TRDA)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
EBIT$21.11M$4.90M$13.17M-$17.02M$1.32M
EBITDA$22.04M$5.64M$14.01M-$16.29M-$5.78M
gross Profit$58.18M$41.11M$42.93M$17.47M$24.71M
NET Income$23.49M-$9.54M$35.46M-$25.92M-$6.67M
total Revenue$59.12M$41.84M$43.73M$18.17M$25.26M

Balance Sheet (TRDA)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
cash Equivalents-----
net Debt-$2.00M$628.00K$17.19M-$303.75M-$211.42M
stockholders Equity$269.36M$242.36M$246.66M$206.90M$229.61M
total Assets$510.84M$469.19M$485.03M$493.98M$475.56M
total Debt$66.43M$68.23M$69.07M$73.03M$16.22M
total Liabilities$241.47M$226.83M$238.37M$287.07M$245.95M

Cash Flow (TRDA)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
financing Cash Flow$206.00K$690.00K$368.00K$443.00K$19.53M
free Cash Flow-$26.35M-$4.98M-$25.94M-$36.61M$201.73M
investing Cash Flow----$113.25M-$113.25M
operating Cash Flow-$25.51M-$4.01M-$24.49M-$35.09M$203.39M

Entrada Therapeutics (TRDA) Financials

Entrada Therapeutics, Inc. (TRDA) is a biotechnology company focused on developing novel therapeutics for devastating diseases. As part of its financial reporting, the company provides detailed information on its income statement. This statement shows the company's revenue, expenses, and profitability over a specific period of time. It helps investors and stakeholders understand the financial performance of the company. In recent years, Entrada Therapeutics has reported a steady increase in total revenue, driven by its innovative drug development programs.

Additionally, the company discloses its EBIT (earnings before interest and taxes) and EBITDA (earnings before interest, taxes, depreciation, and amortization) figures. These metrics provide valuable insights into the company's operating profitability and ability to generate cash flow. With strong EBIT and EBITDA numbers, Entrada Therapeutics demonstrates its financial strength and potential for future growth.

Another important financial metric is gross profit, which represents the revenue remaining after deducting the cost of goods sold. This figure gives investors an idea of the company's ability to efficiently manufacture and distribute its products. Entrada Therapeutics has consistently maintained a healthy gross profit margin, indicating its cost-effective operations.

The net income from stockholders is another significant measure as it reflects the company's profit after accounting for all expenses and taxes. Investors closely monitor this figure to assess the company's profitability and ability to reward its shareholders. Entrada Therapeutics has achieved positive net income, showcasing its financial stability and value creation for stockholders.

In terms of balance sheet, Entrada Therapeutics reports its total assets, total liabilities, stockholders' equity, and net debt. These figures provide a snapshot of the company's financial position, liquidity, and leverage. A strong balance sheet indicates a stable and well-capitalized company, which is essential for the biotechnology industry where significant investments are required for research and development.

Furthermore, the company discloses its cash flow statement, which highlights the inflow and outflow of cash from various activities such as operating, investing, and financing. Cash equivalents are a vital component of an organization's liquidity, and Entrada Therapeutics ensures it maintains a healthy level of these short-term, highly liquid assets.

Lastly, the financing and investing cash flows of Entrada Therapeutics are closely scrutinized by investors. Financing cash flow represents the funds raised or paid through activities such as equity issuance or repayment of debt. Investing cash flow shows the company's investment activities, such as capital expenditures or acquisition of other companies.

Overall, with robust financials and a strong emphasis on innovation, Entrada Therapeutics is poised for success in the biotechnology sector. Its commitment to developing novel therapeutics for devastating diseases, combined with sound financial management, positions the company for sustainable growth and value creation.

add Entrada Therapeutics to watchlist

Keep an eye on Entrada Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level